Abstract Body

Background: Antiretroviral regimens containing tenofovir disoproxil fumarate (TDF) have been associated with decreases in bone mineral density (BMD), and elevations in bone turnover markers (BTM) and intact parathyroid hormone (iPTH) in patients with HIV. Prior cross-sectional studies suggested that a functional vitamin D deficiency may in part explain these changes. To explore this hypothesis further, we measured change in plasma vitamin D binding protein (VDBP) levels from baseline to 48 weeks among a cohort of patients treated with TDF/lamivudine(3TC)/efavirenz(EFV) in the context of other serologic markers of vitamin D and bone metabolism.

Methods: We performed a secondary analysis using plasma samples collected at 0, 24, and 48 weeks after initiation of TDF/3TC/EFV from 140 adult participants enrolled in a multi-center randomized trial. Women over 45 years were excluded to avoid confounding due to menopausal status. Data regarding socio-demographic characteristics, BMI, CD4+ counts, and HIV viral load were obtained as part of the parent study. Laboratory analyses included plasma VDBP, iPTH, total 25-hydroxyvitamin D (25OHD), the bone resorption marker collagen type 1 cross-linked C-telopeptide (CTX), and the bone formation marker total procollagen type 1 N-terminal propeptide (P1NP). Differences between time points were compared using the paired t-test.

Results: Our sample included 110 men and 30 women with a mean age of 33±9.6 yrs. Mean BMI remained stable from 0 to 48 wks (21.7±3.0 v. 22.0±3.2 kg/m2, p=0.20), however mean CD4+ count increased significantly (279.5±117.1 v. 424.6±176.9 cells/mm3, p<0.001) and median viral load decreased from 53767 (IQR: 19802 to 136493) to 0 (IQR:0 to 10) copies/mL. Significant increases were observed in VDBP levels from 0 to 24 wks followed by smaller increases from 24 to 48 wks (see Table 1). Similar increases were detected in iPTH levels, however 25OHD levels remained relatively stable. BTM levels increased significantly from 0 to 24 wks followed by a slight decline (CTX) or stabilization (P1NP), however remained significantly higher compared with baseline at 48 wks.

Conclusions: Plasma levels of VDBP rose significantly in the first 24 wks after initiation of TDF/3TC/EFV, followed by a more modest increase from 24 to 48 wks. This change was observed in concert with elevations iPTH and BTMs, despite stable 25OHD levels, supporting a potential mechanistic role for VDBP in bone loss associated with TDF therapy.

viewer?TAG_ACTION=SECURE_FILE_DOWNLOAD&V